Literature DB >> 35106666

Prognostic Significance of mRNA Expression RBBP8 or Its Methylation in Gliomas.

Zhendong Liu1, Xingbo Cheng1, Shaochong Lin2, Zhibin Han3, Haoran Jin4, Zheyu Luan5, Pengxu Li1, Wenjia Liang6, Rongjun Qian7, Yanzheng Gao8.   

Abstract

Retinoblastoma-binding protein 8 (RBBP8) affects the prognosis of patients with malignancies through various mechanisms. However, its function in gliomas is unknown. Our study explored the effects of RBBP8 on the prognosis of glioma patients, as well as its regulatory role in the glioma immune microenvironment. We used various bioinformatics methods to analyze the transcriptional profiles and methylation data of RBBP8 in gliomas from multiple databases. Our results showed that the mRNA and protein expression of RBBP8 in gliomas was higher than that in normal tissues and positively correlated with malignant clinical features such as age and WHO grade. A Kaplan-Meier analysis showed that patients with high RBBP8 expression had a poor prognosis. Cox regression demonstrated that RBBP8 was an independent risk indicator and had good diagnostic value for the poor prognosis of glioma. Importantly, RBBP8 was positively correlated with many well-known immune checkpoints (e.g., CTLA4 and PDL-1). Finally, a gene set enrichment analysis revealed that RBBP8 was remarkably enriched in cancer-related pathways such as cell cycle, DNA replication and so on. In conclusion, this study is the first to elaborate on the value of RBBP8 in the pathological process of glioma for anti-tumor immunotherapy. In addition, the expression of RBBP8 and its methylation site, cg05513509, may provide potential targets for glioma therapy.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Biomarker; Glioma; Immunotherapy; RBBP8

Year:  2022        PMID: 35106666     DOI: 10.1007/s10571-022-01198-4

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  24 in total

1.  Expression of PCNA-binding domain of CtIP, a motif required for CtIP localization at DNA replication foci, causes DNA damage and activation of DNA damage checkpoint.

Authors:  Bingnan Gu; Phang-Lang Chen
Journal:  Cell Cycle       Date:  2009-05-02       Impact factor: 4.534

Review 2.  Cancer Neoantigens and Applications for Immunotherapy.

Authors:  Alexis Desrichard; Alexandra Snyder; Timothy A Chan
Journal:  Clin Cancer Res       Date:  2015-10-29       Impact factor: 12.531

Review 3.  Glioma epigenetics: From subclassification to novel treatment options.

Authors:  Olga Gusyatiner; Monika E Hegi
Journal:  Semin Cancer Biol       Date:  2017-11-21       Impact factor: 15.707

Review 4.  Immune microenvironment of gliomas.

Authors:  Anna Gieryng; Dominika Pszczolkowska; Kacper A Walentynowicz; Wenson D Rajan; Bozena Kaminska
Journal:  Lab Invest       Date:  2017-03-13       Impact factor: 5.662

Review 5.  Glioma Subclassifications and Their Clinical Significance.

Authors:  Ricky Chen; Matthew Smith-Cohn; Adam L Cohen; Howard Colman
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

6.  Evaluation of genetic risk loci for intracranial aneurysms in sporadic arteriovenous malformations of the brain.

Authors:  P H C Kremer; B P C Koeleman; L Pawlikowska; S Weinsheimer; N Bendjilali; S Sidney; J G Zaroff; G J E Rinkel; L H van den Berg; Y M Ruigrok; G A P de Kort; J H Veldink; H Kim; C J M Klijn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-07-21       Impact factor: 10.154

7.  CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas.

Authors:  Xiudong Guan; Chuanbao Zhang; Jingyan Zhao; George Sun; Qingkun Song; Wang Jia
Journal:  EBioMedicine       Date:  2018-08-18       Impact factor: 8.143

8.  Expression Profile Analysis Identifies a Novel Seven Immune-Related Gene Signature to Improve Prognosis Prediction of Glioblastoma.

Authors:  Li Hu; Zhibin Han; Xingbo Cheng; Sida Wang; Yumeng Feng; Zhiguo Lin
Journal:  Front Genet       Date:  2021-02-23       Impact factor: 4.599

9.  Mechanism of DNA resection during intrachromosomal recombination and immunoglobulin class switching.

Authors:  Anne Bothmer; Philipp C Rommel; Anna Gazumyan; Federica Polato; Colleen R Reczek; Matthias F Muellenbeck; Sonja Schaetzlein; Winfried Edelmann; Phang-Lang Chen; Robert M Brosh; Rafael Casellas; Thomas Ludwig; Richard Baer; André Nussenzweig; Michel C Nussenzweig; Davide F Robbiani
Journal:  J Exp Med       Date:  2012-12-17       Impact factor: 14.307

Review 10.  New emerging targets in cancer immunotherapy: the role of neoantigens.

Authors:  Leticia De Mattos-Arruda; Juan Blanco-Heredia; Carmen Aguilar-Gurrieri; Jorge Carrillo; Julià Blanco
Journal:  ESMO Open       Date:  2020-04
View more
  1 in total

1.  Differential expression of DNA damage repair genes after chemoradiotherapy and inhibition rate in different bladder cancer cells.

Authors:  Shujun Sun; Kehua Jiang; Jin Zeng
Journal:  Transl Androl Urol       Date:  2022-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.